A novel multivalent OspA vaccine against Lyme borreliosis shows promise in Phase I/II studies.
Vaccine R&D, Baxter BioScience, Biomedical Research Centre, Uferstraße 15, A-2304 Orth/Donau, Austria +43 1 20100 244 4316 +43 1 20100 244 5134.
P Noel
PN
Barrett
Daniel
D
Portsmouth
D000907:Antibodies, Bacterial / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology; D000954:Antigens, Surface / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D001425:Bacterial Outer Membrane Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D001428:Bacterial Vaccines / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D008074:Lipoproteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology*; D008193:Lyme Disease / Q000276:immunology / Q000517:prevention & control*
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D000954:Antigens, Surface; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D008074:Lipoproteins; C072045:OspA protein